Biogen requests Anvisa to register Skyclarys

Let's get to the *important* part, thanks largely to @Amalia Maranhao, Director of ABAHE. Look at the Easter gift we've all been waiting for!

Pharmaceutical company Biogen has asked Anvisa for a license to register and market in Brazil the first drug for the treatment of the ultra-rare neurodegenerative disease *Friedreich's Ataxia* called Skyclarys.

The deadline for review stipulated in Anvisa resolution 204 is 120 days, extendable by 40 days. Let's hope it is met and that no requirements are imposed that delay the application's progress.

If you have ataxia, be sure to register at abahe.org.br . This helps attract drug research.

@anvisaoficial #ataxiadefriedreich #ataxia #ataxiadefriedreich2023 #abahe

[Post published on 03/28/2024 by Márcio Galvão]